Research and Markets: Asthma/COPD Market Forecast - 10 Year Country, Indication and Device Specific Forecasts for Individu

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ce28e8/asthmacopd_market) has announced the addition of the "Asthma/COPD Market Forecast" report to their offering.

Introduction

This model contains a 10 year country, indication, and device specific forecasts for individual products used in asthma and COPD, taking into account competitive positioning and key market events

Reasons to Purchase

  • Quantify the size and scope of the asthma and COPD market and the changing market dynamics from 2009-2019
  • Understand asthma and COPD market trends including drivers of success and the impact of changing regulations
  • Gain insight into the recent advances in the asthma and COPD pipeline and access forecasts of 13 novel products

For more information visit http://www.researchandmarkets.com/research/ce28e8/asthmacopd_market

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.